Head and neck squamous cell carcinoma: New translational therapies

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 684-699

  Prince, Anthony ^a   Aguirre Ghizo, Julio ^a   Genden, Eric ^a   Posner, Marshall ^a   Sikora, Andrew ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

head and neck cancer; immunotherapy; minimally invasive surgery; squamous cell carcinoma; targeted therapy; translational research; transoral robotic surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; L N6 (1 IMINOETHYL) LYSINE; METHOTREXATE; N(G) NITROARGININE METHYL ESTER; PANITUMUMAB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EARLY CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; MELANOMA; METASTASIS; PAPILLOMA VIRUS; PATHOGENESIS; PROGNOSIS; REVIEW; ROBOTICS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INDOLES; MALE; MIDDLE AGED; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; TRANSLATIONAL RESEARCH;

EID: 78649681592     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20216     Document Type: Review

References (116)

1. Parkin DM, Bray F, Ferlay J, et al., Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; doi:10.1002/ijc.25516.
3. Jemal A, Siegel R, Xu J, et al., Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
4. Shiboski CH, Schmidt BL, Jordan RC., Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-1849.
5. Vineis P, Alavanja M, Buffler P, et al., Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96: 99-106.
6. Rodriguez T, Altieri A, Chatenoud L, et al., Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004; 40: 207-213.
7. Lee YC, Boffetta P, Sturgis EM, et al., Involuntary smoking and head and neck cancer risk: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17: 1974-1981.
8. Bosetti C, Gallus S, Peto R, et al., Tobacco smoking, smoking cessation, and cumulative risk of upper aerodigestive tract cancers. Am J Epidemiol 2008; 167: 468-473.
9. Warnakulasuriya S., Areca nut use following migration and its consequences. Addict Biol 2002; 7: 127-132.
10. Trivedy CR, Craig G, Warnakulasuriya S., The oral health consequences of chewing areca nut. Addict Biol 2002; 7: 115-125. (Pubitemid 34087915)
11. Freedman ND, Park Y, Subar AF, et al., Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. Int J Cancer 2008; 122: 2330-2336.
12. Perez-Ordoñez B, Beauchemin M, Jordan RC., Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006; 59: 445-453.
13. Reed AL, Califano J, Cairns P, et al., High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3633.
14. Poeta ML, Manola J, Goldwasser MA, et al., TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
15. McCaul JA, Gordon KE, Clark LJ, et al., Telomerase inhibition and the future management of head-and-neck cancer. Lancet Oncol 2002; 3: 280-288.
16. Chung CH, Gillison ML., Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758-6762.
17. D'Souza G, Kreimer AR, Viscidi R, et al., Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
18. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
19. Genden EM., Reconstruction of the mandible and the maxilla: the evolution of surgical technique. Arch Facial Plast Surg 2010; 12: 87-90.
20. Pignon JP, le Maître A, Maillard E, et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
21. Bernier J, Vermorken JB, Koch WM., Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 2006; 24: 2629-2635.
22. Cooper JS, Pajak TF, Forastiere AA, et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
23. Bernier J, Domenge C, Ozsahin M, et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952. (Pubitemid 38580197)
24. Weber RS, Berkey BA, Forastiere A, et al., Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003; 129: 44-49.
25. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
26. Lefebvre JL, Chevalier D, Luboinski B, et al.,; EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-899.
27. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
28. Colevas AD., Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-2652.
29. Forastiere AA, Metch B, Schuller DE, et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
30. Janot F, de Raucourt D, Benhamou E, et al., Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-5523.
31. Salama JK, Vokes EE, Chmura SJ, et al., Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64: 382-391.
32. Rubin Grandis J, Melhem MF, Gooding WE, et al., Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
33. Grandis JR, Tweardy DJ., Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
34. Karamouzis MV, Grandis JR, Argiris A., Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 70-82.
35. Chung CH, Ely K, McGavran L, et al., Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176.
36. Rubin Grandis J, Zeng Q, Tweardy DJ., Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 1996; 2: 237-240.
37. Vermorken JB, Trigo J, Hitt R, et al., Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
38. Bonner JA, Harari PM, Giralt J, et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
39. Cohen EE, Kane MA, List MA, et al., Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-8424.
40. Soulieres D, Senzer NN, Vokes EE, et al., Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
41. Le Tourneau C, Siu LL., Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008; 20: 256-263.
42. Mukohara T, Engelman JA, Hanna NH, et al., Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-1194.
43. Viloria-Petit A, Crombet T, Jothy S, et al., Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
44. Leer JW, Overgaard J, Heeren G., The European core curriculum on radiotherapy. Radiother Oncol 1991; 22: 153-155.
45. Benefield J, Petruzzelli GJ, Fowler S, et al., Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas. Invasion Metastasis 1996; 16: 291-301.
46. Saba NF, Shin DM, Khuri FR., Targeting angiogenesis in head and neck cancer. Curr Cancer Drug Targets 2007; 7: 643-649.
47. Choong NW, Mauer AM, Haraf DJ, et al., Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008; 3: 1003-1011.
48. Jones KL, Buzdar AU., Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-1187.
49. Wheeler DL, Huang S, Kruser TJ, et al., Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-3956.
50. Hay N, Sonenberg N., Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
51. Allen GW, Saba C, Armstrong EA, et al., Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007; 67: 1155-1162.
52. Reiter R, Gais P, Jutting U, et al., Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 5136-5141.
53. Elser C, Siu LL, Winquist E, et al., Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-3773.
54. Williamson SK, Moon J, Huang CH, et al., Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28: 3330-3335.
55. Haddad RI, Shin DM., Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
56. Kao J, Packer S, Vu HL, et al., Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009; 115: 3571-3580.
57. Milano MT, Katz AW, Muhs AG, et al., A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008; 112: 650-658.
58. Salama JK, Chmura SJ, Mehta N, et al., An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 2008; 14: 5255-5259.
59. Holland JF., Breaking the cure barrier 25 years later. J Clin Oncol 2008;; 26: 1575.
60. Choi S, Myers JN., Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy [published correction appears in J Dent Res 2008; 87: 191]. J Dent Res 2008; 87: 14-32.
61. Lin DT, Subbaramaiah K, Shah JP, et al., Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24: 792-799.
62. Kao J, Packer SH, Teng M, et al., Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. J Clin Oncol 2010; 28 ((suppl 15S)abstract):5561.
63. Kao J, Sikora AT, Fu S., Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets 2009; 9: 931-937.
64. Gupta GP, Nguyen DX, Chiang AC, et al., Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-770.
65. Fukumura D, Kashiwagi S, Jain RK., The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534.
66. Ekmekcioglu S, Tang CH, Grimm EA., NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 2005; 5: 103-115.
67. Gallo O, Fabbroni V, Sardi I, et al., Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 2002; 299: 517-524.
68. Brennan PA, Dennis S, Poller D, et al., Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck 2008; 30: 208-214.
69. Tinker AC, Wallace AV., Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 2006; 6: 77-92.
70. Sikora AG, Gelbard A, Davies MA, et al., Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 2010; 16: 1834-1844.
71. Shang ZJ, Li ZB, Li JR., In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. Int J Oral Maxillofac Surg 2006; 35: 539-543.
72. Grandis JR, Pietenpol JA, Greenberger JS, et al., Head and neck cancer: meeting summary and research opportunities. Cancer Res 2004; 64: 8126-8129.
73. Aguirre-Ghiso JA., Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846.
74. Sang L, Coller HA, Roberts JM., Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 2008; 321: 1095-1100.
75. Schmidt-Kittler O, Ragg T, Daskalakis A, et al., From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 7737-7742.
76. Aguirre-Ghiso JA, Estrada Y, Liu D, et al., ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-1695.
77. Pan Y, Haines DS., Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 2000; 19: 3095-3100.
78. Erber R, Conradt C, Homann N, et al., TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
79. Kuss I, Hathaway B, Ferris RL, et al., Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 3755-3762.
80. Lopez-Albaitero A, Nayak JV, Ogino T, et al., Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 3402-3409.
81. Ferris RL, Hunt JL, Ferrone S., Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005; 33: 113-133.
82. Miyazawa M, Ohsawa R, Tsunoda T, et al., Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101: 433-439.
83. Hoffmann TK, Bier H, Whiteside TL., Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004; 53: 1055-1067.
84. Leibowitz MS, Nayak JV, Ferris RL., Head and neck cancer immunotherapy: clinical evaluation. Curr Oncol Rep 2008; 10: 162-169.
85. To WC, Wood BG, Krauss JC, et al., Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126: 1225-1231.
86. Vujanovic NL, Yasumura S, Hirabayashi H, et al., Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol 1995; 154: 281-289.
87. Frumento G, Piazza T, Di Carlo E, et al., Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006; 6: 233-237.
88. Kim R, Emi M, Tanabe K, et al., Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66: 5527-5536.
89. Marigo I, Dolcetti L, Serafini P, et al., Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-179.
90. Mougiakakos D, Choudhury A, Lladser A, et al., Regulatory T cells in cancer. Adv Cancer Res 2010; 107: 57-117.
91. Dolcetti L, Marigo I, Mantelli B, et al., Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267: 216-225.
92. Gabrilovich DI, Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
93. Ozao-Choy J, Ma G, Kao J, et al., The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
94. Kao J, Ko EC, Eisenstein S, et al., Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2010; doi:10.1016/j.critrevonc.2010.02.004.
95. Wirth LJ, Haddad RI, Lindeman NI, et al., Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 6976-6981.
96. Movva S, Verschraegen C., The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther 2009; 9: 231-241.
97. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med 2010;363:1290]. N Engl J Med 2010; 363: 711-723.
98. Lee SC, Lopez-Albaitero A, Ferris RL., Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. Curr Oncol Rep 2009; 11: 156-162.
99. Roda JM, Joshi T, Butchar JP, et al., The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13: 6419-6428.
100. Bibeau F, Lopez-Crapez E, Di Fiore F, et al., Impact of FcIγ RIIa-FcIγ RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
101. Adili A., Robot-assisted orthopedic surgery. Semin Laparosc Surg 2004; 11: 89-98.
102. Hollands CM, Dixey LN., Applications of robotic surgery in pediatric patients. Surg Laparosc Endosc Percutan Tech 2002; 12: 71-76.
103. Boehm DH, Arnold MB, Detter C, et al., Incorporating robotics into an open-heart program. Surg Clin North Am 2003; 83: 1369-1380.
104. Weinstein GS, O'Malley BW Jr, Desai SC, et al., Transoral robotic surgery: does the ends justify the means? Curr Opin Otolaryngol Head Neck Surg 2009; 17: 126-131.
105. Hockstein NG, O'Malley BW Jr, Weinstein GS., Assessment of intraoperative safety in transoral robotic surgery. Laryngoscope 2006; 116: 165-168.
106. Machtay M, Perch S, Markiewicz D, et al., Combined surgery and postoperative radiotherapy for carcinoma of the base of radiotherapy for carcinoma of the base of tongue: analysis of treatment outcome and prognostic value of margin status. Head Neck 1997; 19: 494-499.
107. O'Malley BW Jr, Weinstein GS, Hockstein NG., Transoral robotic surgery (TORS): glottic microsurgery in a canine model. J Voice 2006; 20: 263-268.
108. Hockstein NG, Weinstein GS, O'Malley Jr BW., Maintenance of hemostasis in transoral robotic surgery. ORL J Otorhinolaryngol Relat Spec 2005; 67: 220-224.
109. Weinstein GS, O'Malley BW Jr, Hockstein NG., Transoral robotic surgery: supraglottic laryngectomy in a canine model. Laryngoscope 2005; 115: 1315-1319.
110. Weinstein GS, O'Malley BW Jr, Snyder W, et al., Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133: 1220-1226.
111. Weinstein GS, O'Malley BW Jr, Snyder W, et al., Transoral robotic surgery: supraglottic partial laryngectomy. Ann Otol Rhinol Laryngol 2007; 116: 19-23.
112. O'Malley BW Jr, Weinstein GS, Snyder W, et al., Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006; 116: 1465-1472.
113. Mukhija VK, Sung CK, Desai SC, et al., Transoral robotic assisted free flap reconstruction. Otolaryngol Head Neck Surg 2009; 140: 124-125.
114. Desai SC, Sung CK, Jang DW, et al., Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract. Laryngoscope 2008; 118: 2187-2189.
115. Genden EM, Desai S, Sung CK., Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head Neck 2009; 31: 283-289.
116. Desai SC, Sung CK, Genden EM., Transoral robotic surgery using an image guidance system. Laryngoscope 2008; 118: 2003-2005.